Tag: DurAVR transcatheter heart valve
$38.5M investment to expand Anteris’ manufacturing capacity, global clinical program
Anteris Technologies Global Corp has announced a binding agreement for a private placement valued at approximately AUD 38.5 million (USD 25.2 million) to support the advancement of its PARADIGM clinical trial and accelerate global commercialisation efforts.
Anteris granted utility patent for heart valve replacement technology
Australian biotechnology company Anteris Technologies announced that the United States Patent and Trademark Office has issued a utility patent for its novel DurAVR transcatheter heart valve (THV).
Featured Article
Navigating energy price volatility with predictive intelligence
Energy price volatility has become a structural feature of modern electricity markets rather than a temporary disruption. For energy-intensive manufacturers and large commercial operators, fluctuating wholesale prices are reshaping how energy costs are managed, making reactive approaches increasingly inadequate.
